Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 200 participants.
Also called NCT01529541
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT01529541
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01529541. Randomized; triple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
- Acronym
- CWP-DIANA-302
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Anagliptin
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- JW Pharmaceutical
Record details
- Record id
cardio:ct-nct01529541- Content hash
b532d72675c581d7ec6cd0e64eae5c010bce171ee76c4f9965fa3c1483ba2c2c